Posts Tagged ‘Medicines Company’

RSS

April 16th, 2015

Cangrelor Finally Gets Nod From FDA Advisory Panel

On Wednesday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-2-1 to recommend approval of cangrelor during PCI to reduce the risk of periprocedural thrombotic events such as MI, stent thrombosis, and ischemia driven revascularization. The news follows a decade of efforts to develop the drug — a potent, fast-acting, and reversible  antiplatelet agent. After the failure of two […]